Trichloroethylene, used extensively in industry and the military and a common environmental contaminant, joins other mitochondrial neurotoxins, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and some pesticides, as a risk factor for parkinsonism.

The magnitude of acute pyrethrin/pyrethroid-related illness/injury is relatively low but is increasing. As such, additional measures to prevent them are needed.

Background Each year, 1.2 million metalworkers are exposed to metalworking fluids (MWFs), which can cause dermal and respiratory disease. The National Institute for Occupational Safety and Health (NIOSH) conducted a health hazard evaluation of MWF exposures at an aircraft engine manufacturing facility. The objectives were to determine employee exposures to endotoxin and MWFs in the air, characterize symptoms experienced by employees working with MWFs, compare them to symptoms of employees unexposed to MWFs, and make recommendations for reducing exposures based on results. Methods 407 workers were categorized as MWF exposed or MWF unexposed and completed questionnaires. Estimated prevalence ratios (PR) of dermatitis, asthma, and work-related asthma (WRA) symptoms were calculated. Airborne concentrations of MWF and endotoxin were measured, and work practices observed. Results MWF exposed workers had a significantly higher prevalence of dermatitis on wrists/forearms (PR 2.59; 95% CI 1.22, 5.46), asthma symptoms (PR 1.49; 95% CI 1.05, 2.13) and WRA symptoms (PR 2.10; 95% CI 1.22, 3.30) than unexposed workers. Airborne concentrations of MWF were below the NIOSH recommended exposure limit (REL) for MWF aerosols (thoracic particulate mass). Conclusions Despite MWF exposures below the NIOSH REL, exposed workers had a higher prevalence of asthma, WRA, and dermatitis symptoms than unexposed workers. Recommendations to reduce exposure included configuring mist collectors to automatically turn on when the machine is in use, and enforcing enclosure use.

Tobacco use is a modifiable risk factor that has many characteristics of a chronic illness. We analyzed longitudinal data from participants in the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS) and compared tobacco use to other chronic illnesses to evaluate effects on mortality. We limited our analysis to 20,293 participants aged 45 and older at baseline. We determined smoking status, diabetes status, hypertension, cardiovascular disease (ASCVD), and lung disease status at baseline. We developed Cox proportional hazard models, adjusting for age, sex and race and all comorbid diseases, to determine the effect of disease on mortality at up to 13 years of follow-up, 3,022 study participants died during the follow-up period. Adjusted proportional hazard models found that the risk of smoking for death had a hazard ratio (HR) of 2.0 (95% confidence interval [CI] 1.8, 2.2). This was similar to the mortality risk for ASCVD (HR 1.8, 95% CI 1.7, 2.0), diabetes (HR 1.9, 95% CI 1.7, 2.0), and chronic obstructive pulmonary disease (COPD) (HR 2.1, 95% CI 1.9, 2.4). The risk in former smokers were significantly less than that of current smokers (HR 1.1, 95% CI 1.01, 1.2). In the adjusted models, current cigarette smoking has a mortality risk that is in the same range of that seen in other "chronic diseases", whereas the risk in former smokers is greatly reduced. These data suggest that current smoking should be approached as aggressively as other chronic diseases that are amenable to interventions.